Related references
Note: Only part of the references are listed.Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan
Masashi Mizuguchi et al.
BRAIN & DEVELOPMENT (2019)
Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures
David N. Franz et al.
EPILEPSIA (2018)
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations
Paolo Curatolo et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2018)
Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex
Francois Pierre Combes et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2018)
Current concepts on epilepsy management in tuberous sclerosis complex
Maria Paola Canevini et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2018)
Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial
David N. Franz et al.
NEUROLOGY-CLINICAL PRACTICE (2018)
Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial
Paolo Curatolo et al.
LANCET CHILD & ADOLESCENT HEALTH (2018)
Infantile Lhermitte-Duclos Disease Treated Successfully With Rapamycin
Megan Zak et al.
JOURNAL OF CHILD NEUROLOGY (2017)
Pancreatic tumors in children and young adults with tuberous sclerosis complex
Gonca Koc et al.
PEDIATRIC RADIOLOGY (2017)
Influence of seizures on early development in tuberous sclerosis complex
Jamie K. Capal et al.
EPILEPSY & BEHAVIOR (2017)
Everolimus for the Treatment of Tuberous Sclerosis Complex-Related Cardiac Rhabdomyomas in Pediatric Patients
Nagib Dahdah
JOURNAL OF PEDIATRICS (2017)
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial
FinbarJ K. O'Callaghan et al.
LANCET NEUROLOGY (2017)
mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
David N. Franz et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study
John J. Bissler et al.
PLOS ONE (2017)
Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia
Sarah Weckhuysen et al.
EPILEPSIA (2016)
Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex
Evan J. Hess et al.
EPILEPSIA (2016)
Optical coherence tomography to monitor vigabatrin toxicity in children
Catherine Origlieri et al.
JOURNAL OF AAPOS (2016)
Genetic animal models of malformations of cortical development and epilepsy
Michael Wong et al.
JOURNAL OF NEUROSCIENCE METHODS (2016)
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
Jacqueline A. French et al.
LANCET (2016)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky et al.
LANCET NEUROLOGY (2016)
Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial
Iris E. Overwater et al.
NEUROLOGY (2016)
Long-term treatment of epilepsy with everolimus in tuberous sclerosis
Darcy A. Krueger et al.
NEUROLOGY (2016)
Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
David N. Franz et al.
PLOS ONE (2016)
Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy
Rikke S. Moller et al.
NEUROLOGY-GENETICS (2016)
Everolimus for Subependymal Giant Cell Astrocytoma: 5-Year Final Analysis
David N. Franz et al.
ANNALS OF NEUROLOGY (2015)
Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs
Iris E. Overwater et al.
EPILEPSIA (2015)
Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex
Jeffrey P. MacKeigan et al.
NEURO-ONCOLOGY (2015)
Mechanistic Target of Rapamycin (mTOR) in Tuberous Sclerosis Complex-Associated Epilepsy
Paolo Curatolo
PEDIATRIC NEUROLOGY (2015)
Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments
Anurag Saxena et al.
SEMINARS IN NEUROLOGY (2015)
Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study
Raili Riikonen et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2015)
Clinical features, genetics and potential therapeutic approaches for Birt-Hogg-Dube syndrome
Laura S. Schmidt et al.
EXPERT OPINION ON ORPHAN DRUGS (2015)
The Human Synaptic Vesicle Protein, SV2A, Functions as a Galactose Transporter in Saccharomyces cerevisiae
Marianna Madeo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies
Gordian L. Schmid et al.
PEDIATRIC RESEARCH (2014)
Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Darcy A. Krueger et al.
ANNALS OF NEUROLOGY (2013)
Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex
Daniel Friedman et al.
EPILEPSY & BEHAVIOR (2013)
Clobazam therapy of refractory epilepsy in tuberous sclerosis complex
Melanie Jennesson et al.
EPILEPSY RESEARCH (2013)
mTOR inhibitors as a new therapeutic option for epilepsy
Paolo Curatolo et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
Vigabatrin and Mental Retardation in Tuberous Sclerosis: Infantile Spasms Versus Focal Seizures
Mi-Sun Yum et al.
JOURNAL OF CHILD NEUROLOGY (2013)
Spinal giant cell tumor in tuberous sclerosis: Case report and review of the literature
Mario Francesco Fraioli et al.
JOURNAL OF SPINAL CORD MEDICINE (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler et al.
LANCET (2013)
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
Darcy A. Krueger et al.
NEUROLOGY (2013)
Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
Bo Zhang et al.
PLOS ONE (2013)
Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Darcy A. Krueger et al.
PEDIATRIC NEUROLOGY (2013)
Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Hope Northrup et al.
PEDIATRIC NEUROLOGY (2013)
Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy
Robin C. C. Ryther et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)
Type II focal cortical dysplasia: Electroclinical phenotype and surgical outcome related to imaging
Francine Chassoux et al.
EPILEPSIA (2012)
Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations
Paolo Curatolo et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2012)
Antiepileptic Drugs 2012: Recent Advances and Trends
Joseph I. Sirven et al.
MAYO CLINIC PROCEEDINGS (2012)
Vigabatrin for Childhood Partial-Onset Epilepsies
Hansel M. Greiner et al.
PEDIATRIC NEUROLOGY (2012)
Mechanism of action of vigabatrin: correcting misperceptions
E. Ben-Menachem
ACTA NEUROLOGICA SCANDINAVICA (2011)
The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway
Sharon S. McDaniel et al.
EPILEPSIA (2011)
Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges
Romina Moavero et al.
CHILDS NERVOUS SYSTEM (2010)
The natural history of epilepsy in tuberous sclerosis complex
Catherine J. Chu-Shore et al.
EPILEPSIA (2010)
Early control of seizures improves long-term outcome in children with tuberous sclerosis complex
Roberta Bombardieri et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function
Lynsey Meikle et al.
JOURNAL OF NEUROSCIENCE (2008)
Rapamycin treatment for a child with germline PTEN mutation
Deborah J. Marsh et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: A retrospective open-label trial
James J. Collins et al.
JOURNAL OF CHILD NEUROLOGY (2006)
Clinical pharmacokinetics of everolimus
GI Kirchner et al.
CLINICAL PHARMACOKINETICS (2004)
Lamotrigine therapy of epilepsy in tuberous sclerosis
DN Franz et al.
EPILEPSIA (2001)
Share Paper
